Esophageal cancer other imaging findings

Jump to navigation Jump to search

Esophageal cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Differentiating Esophageal cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Esophageal cancer other imaging findings On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Esophageal cancer other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Esophageal cancer other imaging findings

CDC on Esophageal cancer other imaging findings

Esophageal cancer other imaging findings in the news

Blogs on Esophageal cancer other imaging findings

Directions to Hospitals Treating Esophageal cancer

Risk calculators and risk factors for Esophageal cancer other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Hadeel Maksoud M.D.[2]

Overview

Other imaging studies for esophageal cancer include positron emission tomography scanning with 18-fluorodeoxyglucose (FDG-PET). FDG-PET is a noninvasive staging modality that is more sensitive than CT or EUS for the detection of distant metastases.

Other Imaging Studies

FDG-PET

  • FDG-PET is a noninvasive staging modality that is more sensitive than CT or EUS for the detection of distant metastases.[1][2][3]
  • In 20% of cases, management of esophageal cancer was changed after being scanned with FDG-PET.[2]
  • FDG-PET siginificantly improves the detection of stage IV esophageal cancer.

References

  1. van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD (2008). "Staging investigations for oesophageal cancer: a meta-analysis". Br. J. Cancer. 98 (3): 547–57. doi:10.1038/sj.bjc.6604200. PMC 2243147. PMID 18212745.
  2. 2.0 2.1 Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, Dupont P, Bormans G, Hiele M, De Leyn P, Van Raemdonck D, Coosemans W, Ectors N, Haustermans K, Mortelmans L (2000). "Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma". J. Clin. Oncol. 18 (18): 3202–10. doi:10.1200/JCO.2000.18.18.3202. PMID 10986052.
  3. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD (1997). "Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography". AJR Am J Roentgenol. 168 (2): 417–24. doi:10.2214/ajr.168.2.9016218. PMID 9016218.


Template:WikiDoc Sources